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Abstract: Despite its mild course in immunocompetent individuals, toxoplasmosis 
may have a more painful period in immunosuppressed patients such as hematology 
and oncology patients. This information needs to be known so that it becomes a 
consideration for inclusion in the standard test protocol, especially in patients 
diagnosed with leukemia and lymphoma. Serum samples sent from pediatric and adult 
hematology/oncology outpatient clinic to the Microbiology Laboratory between 
January 2017 and August 2019 were analyzed using Architect Toxo IgG and IgM 
Reagent Kit chemiluminescent microparticulate enzyme immunoassay method on 
Architect system. A total of 673 patient samples belonging to 131 pediatric patients 
and 542 adult patients analyzes in the study. The study group's median age was 29 
(range: 0-83), and 53.5% of them were male. While Toxoplasma gondii IgM positivity 
was 8%, IgG positivity was 28.7%. Toxoplasma gondii IgG seropositivities in male and 
female patients were 27.2% and 30.4% respectively (p=0.44). Toxoplasma gondii IgM 
seropositivities in pediatric and adult patients were 6.9% and 8.3% respectively, and 
IgG seropositivities were 24.4% and 29.7% (p=0.78 and p=0.46 respectively). T. 
gondii IgM positivity was found as 8% and IgG positivity as 28.7% in the study group. 
In conclusion, data obtained from the study were in compliance with both domestic 
and foreign data and the highest rate of IgM and IgG seropositivity was found in 
patients with lymphoma. Given the severe infection in this population, we recommend 
that serologic testing for toxoplasma be added to routine testing when this group of 
patients diagnosis. 




 Toxoplasmosis is one of the most common parasitic infections caused 
by Toxoplasma gondii (T. gondii), a protozoan (Chintakuntlawar et al. 2015). T. 
gondii generally infects warm-blooded vertebrates and humans (Su et al., 2012). 
 T. gondii may transmit by consuming raw or underdone meat contaminated with 
parasite tissue cysts (Pereira, Franco & Leal, 2012). The infection of a woman who 
infects T. gondii during or just before the pregnancy may transmit to the intrauterine 
fetus. It may also transmit by infected blood transfusion and organ transplant from a T. 
gondii positive donor. Besides, people dealing with infected blood at the laboratory are 
also at risk (CDC, 2020). 
 One-third of the world population infects with latent toxoplasmosis. Its incidence 
is higher in underdeveloped countries compared to developed countries 
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(Chintakuntlawar et al., 2015). Seropositivity of T. gondii differs in different regions of 
the world depending on a socioeconomic level, climate, environmental factors, age, 
and contact with animals (Aşcı & Akgün, 2015). Latin America, Eastern and Middle 
Europe, Middle Eastern, and South-Eastern Asia, and Africa regions have the highest 
prevalence (Chintakuntlawar et al., 2015).  
 Primary infections caused by T. gondii are generally asymptomatic or 
characterized by non-specific symptoms. The parasite converts into cyst form on the 
host and creates the latent chronic disease (Lappalainen & Hedman, 2004). Contrary 
to the mild course of toxoplasmosis in immunocompetent individuals, it may have a 
prognostic approach resulting in more severe disease clinics threatening the life of 
immunosuppressed patients (Israelski & Remington, 1993). Therefore, 
immunosuppressive patients such as patients with hematological malignancy 
(especially patients with lymphoma), patients who underwent bone marrow or solid 
organ transplant (including heart, lung, liver, or kidney), and patients with AIDS directly 
targeting the immune system are high-risk groups in terms of toxoplasmosis (Montoya, 
2002). 
 Toxoplasmosis is usually diagnosed with serological tests. These tests are 
generally enzyme immunoassay or immunofluorescence-based tests (Botein et al., 
2019). T. gondii immunoglobulin G (IgG) antibodies investigate to determine whether 
an individual has experienced T. gondii or not. The time of infection, diagnostic 
methods, and avidity tests investigating T. gondii immunoglobulin M (IgM) antibodies 
are used primarily for pregnant women (CDC, 2020). 
 Toxoplasmosis is a fundamental problem as hematology and oncology patients 
with toxoplasmosis both are immunosuppressed and often need a blood transfusion 
as a result of the nature of their diseases. It has a more severe prognostic course and 
causes serious sequela in these patient groups. There are very few studies on the 
seropositivity of T. gondii in the hematology/oncology patient population in our 
country. 
Studies on T. gondii seropositivity rates in Turkey observe to limit with the 
general population and pregnant women (Çiçek et al., 2012; Kasap et al., 2017). The 
number of seropositivity studies in hematology/oncology patients has limits in the last 
ten years. This study aimed to determine whether T. gondii in hematologic and 
oncologic diseases was at alarming seropositivity rates or not. It also sought to obtain 
information about the necessity to investigate anti-Toxoplasma antibodies, especially 
when patients were diagnosed with leukemia and lymphoma. 
 
MATERIALS AND METHOD 
The Ethics Committee approved this study of Gulhane Training and Research 
Hospital at the University of Health Sciences in Turkey (reference number: 
2019/19/419).This study performs as a retrospective, cross-sectional, and descriptive 
survey at Ankara Gulhane Training and Research Hospital in Turkey. A total of 673 
patients’ serum samples sents from pediatric and adult hematology/oncology 
outpatient clinics to Microbiology Laboratory between January 2017 and August 2019. 
Repeated examinations belonging to the same patient excludes from the study, and 
the first evaluation results consider. Serum samples were analyzed using Architect 
Toxo IgG and IgM Reagent Kit (Abbott, Germany) with a chemiluminescent 
microparticulate enzyme immunoassay method on the Architect system (Architect 
i2000SR, Abbott Diagnostics, USA). The results assess according to the assessment 
criteria of the kits. According to the commercial equipment, index values accepted as 
follows: <0.5 was index negative, and ≥0.6 was index positive for toxoplasma IgM 
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antibodies and <1.6 IU/ml was negative, and ≥3.0 IL/ml was positive for toxoplasma 
IgG antibodies. Data analysis performs with SPSS 25 (SPSS Inc, Chicago, IL, USA) 
software program. Compliance of the variables with the normal distribution assesses 
with visual methods (histogram and probability plots) and the Kolmogorov-Smirnov 
test. Quantitative variables compared with Student T-test or Mann Whitney U test and 
qualitative variables with Pearson Chi-Square or Fisher Exact tests. P values of <0.05 
accepted as statistically significant. 
  
RESULTS AND DISCUSSION 
Median age of the patients (131 children and 542 adults; 673 patients in total) 
included in the study was 29 (range=0-83) and 53.5% of 673 patients were male. 
Median ages of T. gondii negative and positive patients were 28 (range=0-83) and 33 
(range=0-80) respectively (p=0.04). While T. gondii IgM positivity was 8% (54/673) 
IgG positivity was 28.7% (193/673). T. gondii IgG seropositivities in male and female 
patients were 27.2% (98/360) and 30.4% (95/313) respectively (p=0.44).  
 
 
Figure 1. Toxo IgM and IgG Seropositivity Rates of Pediatric and Adult 
Hematology/Oncology Patients 
 
   














Pediatric Patient Adult Patient










n (%)  
0-18 122 (93.1) 9 (6.9) - 0.89 
19-39 336 (92.3) 27 (7.4) 1 (0.3) 
40-59 110 (90.2) 12 (9.8) - 
≥60 50 (89.3) 6 (10.7) - 
 Toxo IgG 
0-18 97 (74) 32 (24.4) 2 (1.5) 0.64 
19-39 251(69) 105 (28.8) 8 (2.2) 
40-59 79 (64.8) 41 (33.6) 2 (1.6) 
≥60 41(73.2) 15 (26.8) - 
*p value,  Pearson Chi-Square 
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T. gondii IgM seropositivities in pediatric and adult patients were 6.9% (9/131) 
and 8.3% (45/542) respectively and IgG seropositivities were 24.4% (32/131) and 
29.7% (161/542) (Figure 1) (p=0.78 and p=0.46 respectively). According to the age 
groups, the highest IgM seropositivity rate was found in the age group of 60 years and 
above at a rate of 10.7% (6/56), and the highest IgG seropositivity found in the age 
group of 40-59 years at a rate of 33.6% (41/122) (p=0.81 and p=0.73 respectively) 
(Table 1). 
  
Table 2. Toxoplasma Seropositivity Rates in Pediatric and Adult 
Hematology/Oncology Outpatient Clinics 
 
 Pediatric Patients Adult Patients  
 Hematology 









Toxo IgG      
Negative 64 (70.3) 24 (75) 312 (68.4) 68 (72.3) 0.18 
Positive 27 (29.7) 6 (18.8) 134 (29.4) 26 (27.7)  
Borderline  - 2 (6.3) 10 (2.2) -  
Toxo IgM      
Negative 88 (96.7) 27 (84.4) 420 (92.1) 83 (88.3) 0.28 
Positive 3 (3.3) 5 (15.6) 35 (7.7) 11 (11.7)  
Borderline  - - 1 (0.2) -  
    *p-value,  Pearson Chi-Square 
 
Table 3. Toxo IgM and Toxo IgG Serology Results of Hematology/Oncology Patients 






























102(94.4) 6 (5.6) - 82(75.9) 25(23.1) 1(1) 
Malignancy 
(n=134) 
119(88.8) 15(11.2) - 96(71.6) 37(27.6) 1(0.8) 
Other*  
(n=62) 
58(93.5) 4(6.5) - 40(64.5) 19(30.7) 3(4.8) 
*Other: Fever, Respiratory Tract Infection, pain, general examination, pregnancy, 
emboli/thrombosis, habitual abortus, hypogammaglobulinemia, hypothyroidism  
 
 Toxo IgG seropositivity mostly found in the serum samples sent from pediatric 
(29.7%) and adult (29.4%) hematology outpatient clinics (Table 2). Toxo IgM 
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seropositivity mostly found in patients diagnosed with malignancy (11.4%), and Toxo 
IgG positivity primarily found in bone morrow donors (33.9%) (Table 3). The highest 
Toxo IgM and IgG seropositivity in patients diagnosed with malignancy was found in 
patients with lymphoma (Table 4).  
 
Table 4. Toxo IgM and IgG Seropositivity Rates in Patients Diagnosed  



















40(90.9) 4(9.1)  32(72.7) 11(25) 1(2.3) 
ALL 12 (100) - - 8 (66.6) 4 (33.4) - 
AML 6 (75) 2 (25) - 7 (87.5) 1 (12.5) - 
Multiple 
myeloma 
21(95.5) 1 (4.5) - 17 (77.2) 4 (18.1) 1 (4.5) 
Myelodysplastic 
syndrome 
1(50) 1 (50) - - 2(100) - 
Lymphoma 22 (84.6) 4 (15.4)  17(65.3) 9 (34.7) - 
Hodgkin 
disease 
10 (83.3) 2 (16.7) - 10 (83.3) 2 (16.7) - 
NHL 12 (85.7) 2 (14.3) - 7 (50) 7 (50) - 
Organ 
malignancy 
55 (88.7) 7 (11.3)  45 (72.5) 17(27.5) - 
Brain 3 (75) 1 (2) - 2 (50) 2 (50) - 
Ovary 3 (75) 1 (25) - 3 (75) 1 (25) - 
Testis 45 (93.8) 3 (6.2) - 35 (72.9) 13(27.1) - 
Connective and 
soft tissue 
4 (66.6) 2 (33.4) - 5 (83.3) 1 (16.7) - 
Bone and 
cartilage  
2 (100) - - 2 (50) 2 (50) - 
Total 119 (89) 15 (11) - 96 (72) 37(27.6) 1 (1.4) 
*Line percentage; NHL, Non-Hodgkin lymphoma; ALL, Acute lymphocytic leukemia; 
AML, Acute myelocytic leukemia  
 
 T. gondii infection is common worldwide. While the term toxoplasmosis defines 
the clinical or pathological disease caused by T. gondii, the definition of chronic or 
latent T. gondii infection use for asymptomatic primary infection or parasite 
permanence on tissues (Montoya, 2002). This latent T. gondii infection becomes a 
significant cause of encephalitis, spontaneous abortus, mental retardation, ocular 
disease, and death, especially in immunosuppressive patients, hematology-oncology 
patients (Abdel Malek et al., 2018). The infection causes severe pathological changes 
in fetuses, especially during the intrauterine period and in immunosuppressed patients 
(Khan & Noordin, 2020). Besides, T. gondii infection plays a role in developing various 
disorders such as liver cirrhosis, epilepsy, and even schizophrenia. Recently, reports 
have revealed a possible relationship between T. gondii infection and cancer risk. 
Several studies on that issue have given contradictory results for leukemia (Huang et 
al., 2016). 
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 On the other hand, while toxoplasmosis can frequently provide diagnosis 
serologically in immunocompetent patients, it can generally be diagnosed with the 
combination of several disciplines such as pathology, microbiology, radiology, and 
clinics since serological diagnosis do not give accurate results in immunosuppressive 
patients such as hematology, oncology, and organ transplant patients (Botein et al., 
2019). This matter suggests that there must be more serological data to obtain. 
 T. gondii seroprevalence ranges from 15% to 85% in different regions of Turkey 
(Aşcı & Akgün, 2015). Prevalence rates report to be 10-30% in North America, 
Southeast Asia, Northern Europe, and Sahelian countries of Africa, 30-50% in Eastern 
and Southern Europe and higher in Latin America and tropical African countries 
(Robert-Gangneux & Dardé, 2012).  
 Studies performed in Turkey are mostly related to women at their fertile periods 
and the pregnant population (Çiçek et al., 2012; Kasap et al., 2017). Seroprevalence 
regionally differs between 18.8% and 68.9% in these studies (Senoglu et al., 2018; 
Duran et al., 2017; Okyay et al., 2013). The highest seroprevalence rates in Turkey 
report in the Southeastern Anatolia Region (68.9%), Eastern Anatolia (63%), and 
Mediterranean Region (57%). Toxo IgG positivity rates in studies performed in the 
Central Anatolia Region founders between 26.9% and 36% (Senoglu et al., 2018; 
Duran et al., 2017; Okyay et al., 2013; Malatyalı et al., 2019). In this study, T. 
gondii IgG seropositivity rate in hematology/oncology patients was 28.7%. Our results 
were consistent with regional data. The difference in local seroprevalence rates varies 
depending on geographical factors, climatic characteristics, hygienic conditions, 
dietary habits, and socioeconomic factors (Akduman Alasehir &Yaman, 2018).  
 Although the seropositivity rate was higher in adult patients than in pediatric 
patients, the difference was not significant (Figure 1). Similarly, its report in studies 
performed in Turkey that toxoplasma seroprevalence increases by age (Kaplan et al., 
2014).21 In several worldwide studies, toxoplasmosis seroprevalence in women report 
at higher rates (Wang et al., 2017). Although the seropositivity rate was higher in the 
female gender in numerical value, the data were not statistically significant.  
 T. gondii IgG seropositivity was the highest in serum samples sent from 
pediatric and adult hematology outpatient clinics at the rates of 29.7% and 29.4%, 
respectively (Table 2). When the data obtained from the information system of the 
hospital evaluated T. gondii IgG positivity found to be the highest in bone marrow 
donors (34%). In comparison, positivity rates in patients with blood and blood-forming 
disease and patients with malignancy were 28% and 27%, respectively, and these 
rates were lower compared to bone marrow donors (Table 3). This difference suggests 
that bone marrow donors have been treated more sensitively than hematology and 
oncology patients in terms of T. gondii IgM and IgG seropositivity during donor 
selection and accordingly that more T. gondii IgM and IgG requested. In the study, the 
highest rate of T. gondii IgM and IgG seropositivity founds in patients diagnosed with 
lymphoma (Table 4). T. gondii is an important opportunistic pathogen in the case of 
immunosuppression (CD4 T lymphocyte count: <200 cell/uL) in patients with AIDS 
(Wang et al., 2017). 
 In addition to various malignancy conditions such as leukemia, lymphoma, and 
myeloma, chemotherapy conditions may also reactivate toxoplasmosis (Kojima et al., 
2010; Maciel et al., 2000). It revealed that transplant an infected organ to a 
seronegative receiver was more dangerous than the transmission of a non-infected 
organ to a seropositive receiver (Chehrazi-Raffle et al., 2015). When toxoplasma 
seroprevalence studies in Turkey considered seropositivity rates in 
hematology/oncology patients, this study was consistent with regional results. 
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However, it should not forget that the results found in immunosuppressed patients 
such as patients with HIV/AIDS, patients with cancer, and organ transplant receivers 
will be lower than the actual prevalence due to their insufficient production of specific 
antibodies (Saadatnia & Golkar, 2012). A routine serological screening test 
recommends in patients with immunodeficiency in regions where T. gondii is endemic 
(Wang et al., 2017). Our study's limitations were that Toxo IgM seropositive patients 
could not follow up clinically because it was a retrospective and cross-sectional study. 
 
CONCLUSION  
 Data obtained from the study in compliance with domestic and foreign data with 
the highest IgM and IgG seropositivity rates found in patients with lymphoma. 
Hematology and oncology patients are immunosuppressive patients with positive 
results due to toxoplasmosis reactivation are at risk for reactivation. Patients with 
negative effects are at stake in terms of primary infection. Their results are pseudo-
negative. They cannot give sufficient immunological response, so toxoplasmosis in 
such patients should always be up to date as an issue to consider. 
 
CONFLICT OF INTEREST 
The authors have no potential conflicts of interest regarding this study. 
 
REFERENCE 
Abdel Malek R, Wassef R, Rizk E, Sabry H, Tadros N, Boghdady A. 
(2018).Toxoplasmosis an Overlooked Disease: Seroprevalence in Cancer 
Patients. Asian Pac J Cancer Prev, 19(7):1987-1991. 
Akduman Alasehir E, Yaman G. (2018) Evaluation of Toxoplasma gondii 
Seroprevalence Among Women of Childbearing Age Group in Istanbul. 
Okmeydanı Tıp Dergisi, 34(2), 158-162. 
Aşcı Z, Akgün S. (2015). The Evaluation of Toxoplasma gondii (T.gondii) Serology 
Results Among Cases Who Admitted to the Serology Laboratory of a Hospital in 
Afyon City. Turkiye Parazitol Derg, 39(1): 9-12. 
Botein, E.F., Darwish, A., El-Tantawy, N.L., El-Baz, R., Eid, M.I., & Shaltot, A.M. 
(2019). Serological and molecular screening of umbilical cord blood for 
Toxoplasma gondii infection. Transplant infectious disease : an official journal of 
the Transplantation Society, 21(4), e13117.  
CDC-Toxoplasmosis [Internet]. [cited 2020 Jan 2]. Available from: 
https://www.cdc.gov/parasites/toxoplasmosis/index.html. 
Chehrazi-Raffle, A., Luu, M., Yu, Z., Liou, F., Kittleson, M., Hamilton, M., & 
Kobashigawa, J. (2015). Toxoplasma gondii Serology and Outcomes After Heart 
Transplantation: Contention in the Literature. Transplantation proceedings, 
47(6), 1949–1953. 
Chintakuntlawar, A., Kidd, M., Al-Kali, A., Wilson, W., & Thompson, C.A. (2015). 
Toxoplasmosis in patients with hematologic malignancies. Leukemia & 
lymphoma, 56(2), 536–538. 
Çiçek, A.Ç., Duygu, F., İnakçı, İ.H., Boyar, N., & Boyar, İ.H. (2012). Investigation of 
Toxoplasma gondii antibodies with ELISA among women of childbearing age in 
Şanlıurfa province: A three years evaluation. Journal of Clinical and Experimental 
Investigations, 3(1), 61-65. 
Duran, İ., Nazik, S., Nazik, H., & Duran, Ş. (2017). Evaluation of toxoplasma and 
rubella seropositivity in pregnancy. Balıkesir Med J, 1(1), 22-25. 
Huang, Y., Huang, Y., Chang, A., Wang, J., Zeng, X., & Wu, J. (2016). Is Toxoplasma 
P a g e  | 170 
 
Copyright © 2020, MLTJ, ISSN 2461-0879 
 
Gondii Infection a Risk Factor for Leukemia? An Evidence-Based Meta-Analysis. 
Medical science monitor : international medical journal of experimental and 
clinical research, 22, 1547–1552. 
Israelski, D.M., & Remington, J.S. (1993). Toxoplasmosis in the non-AIDS 
immunocompromised host. Current clinical topics in infectious diseases, 13, 
322–356. 
Kaplan M, Bayar Z, Aslan R, Arı N, Özavcı H, Aşçı Toraman Z. (2014) Toxoplasma 
Seropositivity in Patients Admitted to the Central Laboratory of Firat University 
Hospital with the Suspicion of Toxoplasmosis. F.Ü.Sağ.Bil.Tıp Derg, 28(1): 21 - 
24.  
Kasap, B., Öner, G., Küçük, M., Öztürk Turhan, N., Akın, M.N., Arıkan, S., & Dirgen 
Çaylak, S. (2017). Evaluation of toxoplasmosis, rubella, cytomegalovirus and 
hepatitis prevalence of pregnant women in Muğla. Tepecik Eğitim ve Araştırma 
Hastahanesi Dergisi, 27, 31-36. 
Khan, A.H., & Noordin, R. (2020). Serological and molecular rapid diagnostic tests for 
Toxoplasma infection in humans and animals. European journal of clinical 
microbiology & infectious diseases : official publication of the European Society 
of Clinical Microbiology, 39(1), 19–30. 
Kojima, M., Nakamura, N., Murayama, K., Igarashi, T., Matsumoto, M., Matsuda, H., 
Masawa, N., Miura, I., & Morita, Y. (2010). Reactive lymphoid hyperplasia with 
giant follicles associated with a posttherapeutic state of hematological 
malignancies. A report of eight cases. Tumori, 96(1), 143–148. 
Lappalainen M, Hedman K. (2004). Serodiagnosis of toxoplasmosis. The impact of 
measurement of IgG avidity. Ann Ist Super Sanita, 40(1), 81-88. 
Maciel, E., Siqueira, I., Queiroz, A.C., & Melo, A. (2000). Toxoplasma gondii myelitis 
in a patient with adult T-cell leukemia-lymphoma. Arquivos de neuro-psiquiatria, 
58(4), 1107–1109. 
Malatyalı, E., Yıldız, İ., Tileklioğlu, E., Ertabaklar, H., & Ertuğ, S. (2019). Retrospective 
Analysis of Toxoplasma gondii Serology Results from Adnan Menderes 
University Faculty of Medicine Parasitology Laboratory from 2007 to 2017. 
Türkiye Parazitolojii Dergisi, 43(1), 1. 
Montoya J.G. (2002). Laboratory diagnosis of Toxoplasma gondii infection and 
toxoplasmosis. The Journal of infectious diseases, 185 Suppl 1, S73–S82. 
Pereira KS, Franco RM, Leal DA. (2010). Transmission of toxoplasmosis (Toxoplasma 
gondii) by foods. Adv Food Nutr Res, 60,1-19. 
Robert-Gangneux F, Dardé M.L. (2012). Epidemiology of and diagnostic strategies for 
toxoplasmosis. Clin Microbiol Rev, 25(2), 264-296.   
Saadatnia, G., & Golkar, M. (2012). A review on human toxoplasmosis. Scandinavian 
journal of infectious diseases, 44(11), 805–814. 
Senoglu, S., Yesilbag, Z., Aydin, Ö.A., Karaosmanoglu, H.K., & Yasar, K.K. (2018). 
HIV/AIDS Hastalarinda Toxoplasma gondu IgG Seroprevalansi/Toxoplasma 
gondu IgG Seroprevalence in Patients with HIV/AIDS. Turkish Journal of 
Parasitology, 42(3),175-180.  
Su, C., Khan, A., Zhou, P., Majumdar, D., Ajzenberg, D., Dardé, M.L., Zhu, X.Q., 
Ajioka, J.W., Rosenthal, B.M., Dubey, J.P., & Sibley, L.D. (2012). Globally 
diverse Toxoplasma gondii isolates comprise six major clades originating from a 
small number of distinct ancestral lineages. Proceedings of the National 
Academy of Sciences of the United States of America, 109(15), 5844–5849. 
Okyay, A.G., Karateke, A., Yula, E., Inci, M., Şilfeler, D.B., Motor, V.K., ... & Okur, M. 
(2013) Seroprevalance of Toxoplasma IgG Among Pregnant Women in The 
P a g e  | 171 
 
Copyright © 2020, MLTJ, ISSN 2461-0879 
 
Provınce of Hatay and Contrıbutıon of Avıdıty Test to The Dıagnose.  Journal of 
Turkish Society of Obstetric and Gynecology, 10, 160-164. 
Wang, Z.D., Liu, H.H., Ma, Z.X., Ma, H.Y., Li, Z.Y., Yang, Z.B., Zhu, X.Q., Xu, B., Wei, 
F., & Liu, Q. (2017). Toxoplasma gondii Infection in Immunocompromised 
Patients: A Systematic Review and Meta-Analysis. Frontiers in microbiology, 8, 
389. 
 
 
